Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 270

1.

The Combined Use of Drainage Amylase Concentration and Serum C-reactive Protein as Predictors of Pancreas-Related Complications after Elective Gastrectomy.

Wakahara T, Kanemitsu K, Asari S, Tsuchida S, Ueno N, Toyokawa A, Sasako M.

Oncology. 2019 Oct 10:1-6. doi: 10.1159/000503581. [Epub ahead of print]

PMID:
31600759
2.

Propagermanium Induces NK Cell Maturation and Tends to Prolong Overall Survival of Patients With Refractory Cancer.

Kikuchi S, Noguchi K, Wakai K, Hamazaki Y, Tozawa K, Jomori T, Sasako M, Miwa H.

Anticancer Res. 2019 Sep;39(9):4687-4698. doi: 10.21873/anticanres.13651.

PMID:
31519568
3.

Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis (JCOG1002).

Takahari D, Ito S, Mizusawa J, Katayama H, Terashima M, Sasako M, Morita S, Nomura T, Yamada M, Fujiwara Y, Kimura Y, Ikeda A, Kadokawa Y, Sano T; Stomach Cancer Study Group of the Japan Clinical Oncology Group.

Gastric Cancer. 2019 Sep 12. doi: 10.1007/s10120-019-01007-w. [Epub ahead of print]

PMID:
31515693
4.

An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis.

Katayama H, Tsuburaya A, Mizusawa J, Nakamura K, Katai H, Imamura H, Nashimoto A, Fukushima N, Sano T, Sasako M.

Gastric Cancer. 2019 Jul 1. doi: 10.1007/s10120-019-00981-5. [Epub ahead of print]

PMID:
31264058
5.

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.

Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510. doi: 10.1016/S2468-1253(19)30083-4. Epub 2019 May 14.

PMID:
31101534
6.

Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).

Terashima M, Iwasaki Y, Mizusawa J, Katayama H, Nakamura K, Katai H, Yoshikawa T, Ito Y, Kaji M, Kimura Y, Hirao M, Yamada M, Kurita A, Takagi M, Boku N, Sano T, Sasako M; Stomach Cancer Study Group, Japan Clinical Oncology Group.

Gastric Cancer. 2019 Sep;22(5):1044-1052. doi: 10.1007/s10120-019-00941-z. Epub 2019 Mar 2.

PMID:
30827001
7.

Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial.

Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, Kaji M, Fukushima N, Hato S, Choda Y, Yabusaki H, Yoshida K, Ito S, Takeno A, Yasuda T, Kawachi Y, Katayama H, Fukuda H, Boku N, Sano T, Sasako M.

Lancet Gastroenterol Hepatol. 2019 Mar;4(3):208-216. doi: 10.1016/S2468-1253(18)30383-2. Epub 2019 Jan 22. Erratum in: Lancet Gastroenterol Hepatol. 2019 Apr;4(4):e3.

PMID:
30679107
8.

Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.

Nakamura Y, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, Misawa K, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Bando H, Kawashima Y, Fukunaga T, Gotoh M, Ishibashi T, Shitara K.

Ann Surg Oncol. 2019 Feb;26(2):465-472. doi: 10.1245/s10434-018-7063-8. Epub 2018 Nov 19.

PMID:
30456678
9.

A phase III trial to confirm modified S-1 adjuvant chemotherapy for pathological stage II/III vulnerable elderly gastric cancer patients who underwent gastric resection (JCOG1507, BIRDIE).

Mizutani T, Yamaguchi K, Mizusawa J, Ito S, Nishida Y, Yabusaki H, Boku N, Sano T, Yoshida K, Sasako M, Yoshikawa T, Terashima M; Stomach Cancer Study Group/Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2018 Dec 1;48(12):1101-1104. doi: 10.1093/jjco/hyy152.

PMID:
30346560
10.

Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients.

Ito S, Fukagawa T, Noda M, Hu Q, Nambara S, Shimizu D, Kuroda Y, Eguchi H, Masuda T, Sato T, Katai H, Sasako M, Mimori K.

Ann Surg Oncol. 2018 Nov;25(12):3755-3763. doi: 10.1245/s10434-018-6739-4. Epub 2018 Sep 10.

PMID:
30203407
11.

Universalization of the operative strategy by systematic mesogastric excision for stomach cancer with that for total mesorectal excision and complete mesocolic excision colorectal counterparts.

Shinohara H, Kurahashi Y, Haruta S, Ishida Y, Sasako M.

Ann Gastroenterol Surg. 2017 Oct 23;2(1):28-36. doi: 10.1002/ags3.12048. eCollection 2018 Jan. Review.

12.

Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry).

Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, Fujiwara K, Nakamura M, Kimura T, Ibusuki K, Sakon M.

BMJ Open. 2018 May 30;8(5):e018910. doi: 10.1136/bmjopen-2017-018910.

13.

Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial.

Kurokawa Y, Doki Y, Mizusawa J, Terashima M, Katai H, Yoshikawa T, Kimura Y, Takiguchi S, Nishida Y, Fukushima N, Iwasaki Y, Kaji M, Hirao M, Katayama H, Sasako M.

Lancet Gastroenterol Hepatol. 2018 Jul;3(7):460-468. doi: 10.1016/S2468-1253(18)30090-6. Epub 2018 Apr 28.

PMID:
29709558
14.
15.

[A Case of Stage IV Gastric Cancer Which Showed Pathological Complete Response after Neo-Adjuvant Chemotherapy].

Nakao E, Ozawa R, Takii M, Kaibe N, Kurahashi Y, Oshima T, Niwa H, Kikuchi S, Sasako M, Shinohara H.

Gan To Kagaku Ryoho. 2018 Apr;45(4):667-669. Japanese.

PMID:
29650829
16.

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.

Al-Batran SE, Goetze TO, Mueller DW, Vogel A, Winkler M, Lorenzen S, Novotny A, Pauligk C, Homann N, Jungbluth T, Reissfelder C, Caca K, Retter S, Horndasch E, Gumpp J, Bolling C, Fuchs KH, Blau W, Padberg W, Pohl M, Wunsch A, Michl P, Mannes F, Schwarzbach M, Schmalenberg H, Hohaus M, Scholz C, Benckert C, Knorrenschild JR, Kanngießer V, Zander T, Alakus H, Hofheinz RD, Roedel C, Shah MA, Sasako M, Lorenz D, Izbicki J, Bechstein WO, Lang H, Moenig SP.

BMC Cancer. 2017 Dec 28;17(1):893. doi: 10.1186/s12885-017-3918-9.

17.

Erratum to: Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial.

Maehara Y, Shirabe K, Kohnoe S, Emi Y, Oki E, Kakeji Y, Baba H, Ikeda M, Kobayashi M, Takayama T, Natsugoe S, Haraguchi M, Yoshida K, Terashima M, Sasako M, Yamaue H, Kokudo N, Uesaka K, Uemoto S, Kosuge T, Sawa Y, Shimada M, Doki Y, Yamamoto M, Taketomi A, Takeuchi M, Akazawa K, Yamanaka T, Shimokawa M.

Surg Today. 2017 Dec;47(12):1539-1540. doi: 10.1007/s00595-017-1589-4.

PMID:
28956067
18.

TOP2A, GGH, and PECAM1 are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study.

Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M; ACTS-GC Group.

Oncotarget. 2017 Mar 4;8(34):57574-57582. doi: 10.18632/oncotarget.15895. eCollection 2017 Aug 22.

19.

Is there role for laparoscopic gastrectomy for advanced gastric cancer.

Sasako M.

Eur J Surg Oncol. 2017 Jun;43(6):965-967. doi: 10.1016/j.ejso.2017.02.016. Epub 2017 Mar 8. No abstract available.

PMID:
28330823
20.

The Asian Perspective on the Surgical and Adjuvant Management of Esophagogastric Cancer.

Kurokawa Y, Sasako M.

Surg Oncol Clin N Am. 2017 Apr;26(2):213-224. doi: 10.1016/j.soc.2016.10.011. Review.

PMID:
28279465
21.

Impact of intra-abdominal absorbable sutures on surgical site infection in gastrointestinal and hepato-biliary-pancreatic surgery: results of a multicenter, randomized, prospective, phase II clinical trial.

Maehara Y, Shirabe K, Kohnoe S, Emi Y, Oki E, Kakeji Y, Baba H, Ikeda M, Kobayashi M, Takayama T, Natsugoe S, Haraguchi M, Yoshida K, Terashima M, Sasako M, Yamaue H, Kokudo N, Uesaka K, Uemoto S, Kosuge T, Sawa Y, Shimada M, Doki Y, Yamamoto M, Taketomi A, Takeuchi M, Akazawa K, Yamanaka T, Shimokawa M.

Surg Today. 2017 Sep;47(9):1060-1071. doi: 10.1007/s00595-017-1480-3. Epub 2017 Feb 23. Review. Erratum in: Surg Today. 2017 Sep 27;:.

PMID:
28233105
22.

A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A).

Fukagawa T, Katai H, Mizusawa J, Nakamura K, Sano T, Terashima M, Ito S, Yoshikawa T, Fukushima N, Kawachi Y, Kinoshita T, Kimura Y, Yabusaki H, Nishida Y, Iwasaki Y, Lee SW, Yasuda T, Sasako M; Stomach Cancer Study Group of the Japan Clinical Oncology Group.

Gastric Cancer. 2018 Jan;21(1):68-73. doi: 10.1007/s10120-017-0701-1. Epub 2017 Feb 13.

PMID:
28194522
23.

[Clinical Outcomes of Local Therapy for Lymph Node Recurrence after Radical Esophagectomy for Esophageal Cancer].

Takemura M, Nakao E, Ozawa R, Takii M, Kaibe N, Niwa H, Oshima T, Kikuchi S, Sasako M.

Gan To Kagaku Ryoho. 2016 Nov;43(12):1493-1495. Japanese.

PMID:
28133034
24.

Randomized clinical trial comparing standard diet with perioperative oral immunonutrition in total gastrectomy for gastric cancer.

Ida S, Hiki N, Cho H, Sakamaki K, Ito S, Fujitani K, Takiguchi N, Kawashima Y, Nishikawa K, Sasako M, Aoyama T, Honda M, Sato T, Nunobe S, Yoshikawa T.

Br J Surg. 2017 Mar;104(4):377-383. doi: 10.1002/bjs.10417. Epub 2017 Jan 10.

PMID:
28072447
25.

[Two Resected Cases with Superficial Basaloid Squamous Carcinoma of the Esophagus].

Takii M, Takemura M, Kaibe N, Ohshima T, Kikuchi S, Sasako M.

Gan To Kagaku Ryoho. 2016 Nov;43(11):1381-1384. Japanese.

PMID:
27899779
26.

Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma.

Yamashita H, Seto Y, Sano T, Makuuchi H, Ando N, Sasako M; Japanese Gastric Cancer Association and the Japan Esophageal Society.

Gastric Cancer. 2017 Mar;20(Suppl 1):69-83. doi: 10.1007/s10120-016-0663-8. Epub 2016 Oct 28.

PMID:
27796514
27.

Short-term surgical outcomes from a phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric cancer: Japan Clinical Oncology Group Study JCOG0912.

Katai H, Mizusawa J, Katayama H, Takagi M, Yoshikawa T, Fukagawa T, Terashima M, Misawa K, Teshima S, Koeda K, Nunobe S, Fukushima N, Yasuda T, Asao Y, Fujiwara Y, Sasako M.

Gastric Cancer. 2017 Jul;20(4):699-708. doi: 10.1007/s10120-016-0646-9. Epub 2016 Oct 7.

PMID:
27718137
28.

Institutional variation in short- and long-term outcomes after surgery for gastric or esophagogastric junction adenocarcinoma: correlative study of two randomized phase III trials (JCOG9501 and JCOG9502).

Kurokawa Y, Yamaguchi T, Sasako M, Sano T, Mizusawa J, Nakamura K, Fukuda H.

Gastric Cancer. 2017 May;20(3):508-516. doi: 10.1007/s10120-016-0636-y. Epub 2016 Aug 27.

PMID:
27568321
29.

Non-Randomized Confirmatory Trial of Laparoscopy-Assisted Total Gastrectomy and Proximal Gastrectomy with Nodal Dissection for Clinical Stage I Gastric Cancer: Japan Clinical Oncology Group Study JCOG1401.

Kataoka K, Katai H, Mizusawa J, Katayama H, Nakamura K, Morita S, Yoshikawa T, Ito S, Kinoshita T, Fukagawa T, Sasako M; Stomach Cancer Study Group/Japan Clinical Oncology Group.

J Gastric Cancer. 2016 Jun;16(2):93-7. doi: 10.5230/jgc.2016.16.2.93. Epub 2016 Jun 24.

30.

A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.

Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, Kawashima Y, Kinoshita T, Terashima M, Nashimoto A, Nakamori M, Onaya H, Sasako M.

Gastric Cancer. 2017 Mar;20(2):322-331. doi: 10.1007/s10120-016-0619-z. Epub 2016 Jun 14.

PMID:
27299887
31.

Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma.

Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, Nashimoto A, Ito S, Kaji M, Imamura H, Fukushima N, Fujitani K; Stomach Cancer Study Group of the Japan Clinical Oncology Group.

Ann Surg. 2017 Feb;265(2):277-283. doi: 10.1097/SLA.0000000000001814.

PMID:
27280511
32.

Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).

Tsuburaya A, Sugimoto N, Imamura H, Nishikawa K, Imamoto H, Tsujinaka T, Esaki T, Horita Y, Kimura Y, Fujiya T, Takayama O, Oono R, Yabusaki H, Taguri M, Morita S, Yamada Y, Tan P, Ninomiya M, Furukawa H, Sasako M.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):e45-51. doi: 10.1016/j.clon.2016.04.001. Epub 2016 Apr 30.

PMID:
27142170
33.

Added value of pretreatment (18)F-FDG PET/CT for staging of advanced gastric cancer: Comparison with contrast-enhanced MDCT.

Kawanaka Y, Kitajima K, Fukushima K, Mouri M, Doi H, Oshima T, Niwa H, Kaibe N, Sasako M, Tomita T, Miwa H, Hirota S.

Eur J Radiol. 2016 May;85(5):989-95. doi: 10.1016/j.ejrad.2016.03.003. Epub 2016 Mar 4.

PMID:
27130061
34.

Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.

Fuse N, Bando H, Chin K, Ito S, Yoshikawa T, Tsuburaya A, Terashima M, Kawashima Y, Fukunaga T, Gotoh M, Emi Y, Yoshida K, Oki E, Takahashi S, Kuriki H, Sato K, Sasako M.

Gastric Cancer. 2017 Mar;20(2):332-340. doi: 10.1007/s10120-016-0606-4. Epub 2016 Mar 8.

35.

Integrated Molecular Profiling of Human Gastric Cancer Identifies DDR2 as a Potential Regulator of Peritoneal Dissemination.

Kurashige J, Hasegawa T, Niida A, Sugimachi K, Deng N, Mima K, Uchi R, Sawada G, Takahashi Y, Eguchi H, Inomata M, Kitano S, Fukagawa T, Sasako M, Sasaki H, Sasaki S, Mori M, Yanagihara K, Baba H, Miyano S, Tan P, Mimori K.

Sci Rep. 2016 Mar 3;6:22371. doi: 10.1038/srep22371.

36.

Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.

Ichikawa W, Terashima M, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M.

Gastric Cancer. 2017 Mar;20(2):263-273. doi: 10.1007/s10120-016-0600-x. Epub 2016 Feb 16.

37.

Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.

Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators.

Lancet Oncol. 2016 Mar;17(3):309-18. doi: 10.1016/S1470-2045(15)00553-7. Epub 2016 Jan 26.

PMID:
26822397
38.

[Clinical Outcomes and Prognosis of Salvage Thoracoscopic Esophagectomy after Definitive Chemoradiotherapy].

Takemura M, Takii M, Kaibe N, Niwa H, Oshima T, Kikuchi S, Sasako M.

Gan To Kagaku Ryoho. 2015 Nov;42(12):1469-71. Japanese.

PMID:
26805066
39.

Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis.

Markar SR, Mikhail S, Malietzis G, Athanasiou T, Mariette C, Sasako M, Hanna GB.

Ann Surg. 2016 Jun;263(6):1092-101. doi: 10.1097/SLA.0000000000001542. Review.

PMID:
26797324
40.

Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.

Shitara K, Chin K, Yoshikawa T, Katai H, Terashima M, Ito S, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Tsujinaka T.

Gastric Cancer. 2017 Jan;20(1):175-181. doi: 10.1007/s10120-015-0581-1. Epub 2015 Dec 1.

PMID:
26626800
41.

Incidence of lymph node metastasis in intramucosal gastric cancer measuring 30 mm or less, with ulceration; mixed, predominantly differentiated-type histology; and no lymphovascular invasion: a multicenter retrospective study.

Takizawa K, Ono H, Yamamoto Y, Katai H, Hori S, Yano T, Umegaki E, Sasaki S, Iizuka T, Kawagoe K, Shimoda T, Muto M, Sasako M.

Gastric Cancer. 2016 Oct;19(4):1144-1148. doi: 10.1007/s10120-015-0569-x. Epub 2015 Nov 17.

PMID:
26577295
42.

A randomized Phase II trial of systemic chemotherapy with and without trastuzumab followed by surgery in HER2-positive advanced gastric or esophagogastric junction adenocarcinoma with extensive lymph node metastasis: Japan Clinical Oncology Group study JCOG1301 (Trigger Study).

Kataoka K, Tokunaga M, Mizusawa J, Machida N, Katayama H, Shitara K, Tomita T, Nakamura K, Boku N, Sano T, Terashima M, Sasako M; Stomach Cancer Study Group/Japan Clinical Oncology Group.

Jpn J Clin Oncol. 2015 Nov;45(11):1082-6. doi: 10.1093/jjco/hyv134. Epub 2015 Sep 9.

PMID:
26355164
43.

Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria.

Katayama H, Kurokawa Y, Nakamura K, Ito H, Kanemitsu Y, Masuda N, Tsubosa Y, Satoh T, Yokomizo A, Fukuda H, Sasako M.

Surg Today. 2016 Jun;46(6):668-85. doi: 10.1007/s00595-015-1236-x. Epub 2015 Aug 20.

44.

Asymptomatic Free Air Caused by Mallory-Weiss Tears during Endoscopy.

Kono T, Watari J, Hara K, Ikeda H, Tomita T, Oshima T, Fukui H, Sasako M, Miwa H.

Intern Med. 2015;54(15):1865-8. doi: 10.2169/internalmedicine.54.4375. Epub 2015 Aug 1.

45.

Follow-up after gastrectomy for cancer: the Charter Scaligero Consensus Conference.

Baiocchi GL, D'Ugo D, Coit D, Hardwick R, Kassab P, Nashimoto A, Marrelli D, Allum W, Berruti A, Chandramohan SM, Coburn N, Gonzàlez-Moreno S, Hoelscher A, Jansen E, Leja M, Mariette C, Meyer HJ, Mönig S, Morgagni P, Ott K, Preston S, Rha SY, Roviello F, Sano T, Sasako M, Shimada H, Schuhmacher C, So Bok-Yan J, Strong V, Yoshikawa T, Terashima M, Ter-Ovanesov M, Van der Velde C, Memo M, Castelli F, Pecorelli S, Detogni C, Kodera Y, de Manzoni G.

Gastric Cancer. 2016 Jan;19(1):15-20. doi: 10.1007/s10120-015-0513-0. Epub 2015 Jul 4.

46.

FGF9 from cancer-associated fibroblasts is a possible mediator of invasion and anti-apoptosis of gastric cancer cells.

Sun C, Fukui H, Hara K, Zhang X, Kitayama Y, Eda H, Tomita T, Oshima T, Kikuchi S, Watari J, Sasako M, Miwa H.

BMC Cancer. 2015 Apr 30;15:333. doi: 10.1186/s12885-015-1353-3.

47.

[Treatment outcomes of patients with cervical lymph node recurrence after esophagectomy for esophageal cancer].

Takemura M, Kaibe N, Takii M, Yoshida K, Niwa H, Oshima T, Kikuchi S, Sasako M.

Gan To Kagaku Ryoho. 2014 Nov;41(12):2010-2. Japanese.

PMID:
25731405
48.

Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review.

Markar SR, Wiggins T, Ni M, Steyerberg EW, Van Lanschot JJ, Sasako M, Hanna GB.

Lancet Oncol. 2015 Jan;16(1):e23-31. doi: 10.1016/S1470-2045(14)70419-X. Epub 2014 Dec 29. Review.

PMID:
25638550
49.

Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia.

Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, Ito S, Kurita A, Mizusawa J, Nakamura K; Japan Clinical Oncology Group (JCOG9502).

Br J Surg. 2015 Mar;102(4):341-8. doi: 10.1002/bjs.9764. Epub 2015 Jan 21.

50.

Erratum to: Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer.

Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H.

Gastric Cancer. 2015 Jul;18(3):549. doi: 10.1007/s10120-014-0428-1. No abstract available.

Supplemental Content

Loading ...
Support Center